Support chat
Start a conversation with support.
No messages yet. Send details and an agent will respond. If unavailable, email support@copperstateresearch.local.
14 products
VIP (2mg) / BPC-157 (500mcg) is a dual-function oral peptide blend designed to support immune response, tissue healing, and epithelial protection across the respiratory and gastrointestinal systems. Aviptadil, a synthetic VIP analog, promotes vasodilation, reduces inflammation, and supports lung and gut lining integrity by acting on VIP receptors in epithelial tissues. BPC-157 complements the blend by accelerating tissue regeneration, enhancing angiogenesis, and protecting the GI tract from inflammation and injury. This combination is ideal for research into systemic recovery, immune modulation, and multi-organ healing pathways. Formulated for comprehensive repair and inflammation support, our VIP& BPC-157 blend offers a potent, research-driven approach to epithelial and immune health.
Tesofensine (500mcg) is a powerful weight loss compound that inhibits the reuptake of dopamine, serotonin, and norepinephrine, effectively reducing appetite and food cravings. This compound boosts fat metabolism, promoting significant fat loss and making it ideal for individuals seeking to improve body composition and achieve sustainable weight loss. By regulating hunger signals, Tesofensine helps users manage caloric intake more easily, leading to long-term weight management without the discomfort of constant hunger. Tesofensine is also associated with improved mood and elevated energy levels, enhancing overall well-being while supporting weight loss efforts. Perfect for individuals aiming to control appetite, reduce body fat, and achieve lasting weight management, Tesofensine (500mcg) Capsules x30 offer an effective solution for reaching fitness and health goals.
Tesofensine (500mcg) is a potent weight loss compound that works by inhibiting the reuptake of neurotransmitters such as dopamine, serotonin, and norepinephrine, leading to a significant reduction in appetite and food cravings. This compound has been shown to enhance fat metabolism and promote fat loss, making it highly effective for individuals looking to reduce body weight and improve body composition. Tesofensine helps regulate hunger signals, supporting long-term weight management by making it easier to adhere to reduced caloric intake without the discomfort of persistent hunger. In addition to its appetite-suppressing effects, Tesofensine has been associated with improved mood and increased energy levels, further contributing to its efficacy in weight management programs. Ideal for individuals seeking a powerful tool for reducing body fat and controlling appetite, Tesofensine (500mcg) Capsules x100 offer a safe and effective solution for achieving sustainable weight loss results.
• Composition and format Tesofensine (250 mcg) / Dihexa (10 mg) is a fixed-combination research formulation supplied as solid-format tablets for controlled laboratory workflows. Each tablet contains 250 mcg of tesofensine and 10 mg of dihexa, with 60 tablets per container. The batch-specific Certificate of Analysis (COA) documents active-component identities, per-tablet content verification, physical characteristics, and relevant excipient information to support reproducibility, mass-balance calculations, and documentation control in research environments. • Analytical verification Each production lot is qualified at 99%+ purity by high-performance liquid chromatography, with compound identities confirmed by mass spectrometry. Independent third-party laboratories corroborate in-house analytical results to maintain traceable quality metrics appropriate for research use. • Intended research use Tesofensine / Dihexa is evaluated exclusively in controlled in-vitro systems investigating monoaminergic signaling dynamics, neurotrophic pathway modulation, and synaptic signaling models under defined assay conditions. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This multi-analyte formulation is characterized for use as a research tool in analytical and cell-based models examining interactions between neurotransmitter reuptake modulation and hepatocyte growth factor–related signaling pathways. In controlled in-vitro environments, researchers employ the formulation to study synaptic signaling behavior, receptor- and transporter-associated responses, neuroplasticity-related pathway activation, and pathway cross-talk between small-molecule and peptide-mimetic components. Representative applications include assay development, comparative concentration-response profiling, time-course analyses, and mechanistic investigations of neurochemical signaling strictly within laboratory settings. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. Certificates of Analysis, raw-material sourcing from vetted suppliers, and complete batch documentation are maintained to support institutional procurement review, traceability, and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use
Research-grade catalog item.
SLU-PP-332 (250mcg) is a potent small-molecule REV-ERB agonist that regulates circadian rhythm and enhances mitochondrial activity, making it a powerful compound for metabolic research. This compound has been shown to increase fat oxidation and energy expenditure by activating REV-ERBα/β nuclear receptors, which are central to lipid metabolism and biological clock regulation. SLU-PP-332 supports a shift toward greater energy utilization and metabolic efficiency, making it highly relevant for studies targeting obesity, metabolic syndrome, and weight loss. By modulating the circadian system, SLU-PP-332 may also play a role in optimizing sleep-wake cycles, hormonal balance, and overall energy homeostasis. Ideal for researchers exploring fat loss, endurance, and mitochondrial performance, SLU-PP-332 (250mcg) Tablets x60 provide a targeted approach to investigating advanced metabolic pathways.
SLU-PP-332 (1mg) is a potent small-molecule REV-ERB agonist that regulates circadian rhythm and enhances mitochondrial activity, making it a powerful compound for metabolic research. This compound has been shown to increase fat oxidation and energy expenditure by activating REV-ERBα/β nuclear receptors, which are central to lipid metabolism and biological clock regulation. SLU-PP-332 supports a shift toward greater energy utilization and metabolic efficiency, making it highly relevant for studies targeting obesity, metabolic syndrome, and weight loss. By modulating the circadian system, SLU-PP-332 may also play a role in optimizing sleep-wake cycles, hormonal balance, and overall energy homeostasis.
• Composition and format MK-677 (Ibutamoren) 25 mg × 60 tablets is a solid-matrix small-molecule research formulation supplied as sixty 25 mg compressed units per container. Batch COAs document identity, net content per unit, and formulation details (including excipient profile, if applicable) to support method reproducibility and documentation control. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use MK-677 is provided for controlled in-vitro and ex-vivo investigations into ghrelin receptor pathway characterization, assay development, and receptor-ligand interaction profiling. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes. • Research characteristics and applications This solid-dose format enables dissolution testing, stability profiling, impurity tracking, and comparative method validation under defined laboratory conditions. Representative applications include matrix-assisted delivery modeling, receptor binding/activation studies, and forced-degradation assessments to inform analytical method suitability. Language avoids functional or outcome claims and adheres to ABM’s safe-phrasing standards. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use
• Composition and format Methblue (25 mg) / Methylliberine (50 mg) x 60 Tablets is a fixed-combination research formulation supplied as solid-format tablets for controlled laboratory workflows. Each tablet contains 25 mg of methylene blue and 50 mg of methylliberine, with 60 tablets per container. The batch-specific Certificate of Analysis (COA) details active-component identities, per-unit content, physical form, and relevant excipient information, supporting method-level reproducibility, mass-balance calculations, and documentation control in research environments. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use Methblue (25 mg) / Methylliberine (50 mg) is evaluated in controlled in-vitro systems interrogating mitochondrial redox cycling, electron-transport-associated pathways, and neuroactive signaling models, including studies of monoamine- and adenosine-associated mechanisms under defined assay conditions. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This combination of methylene blue and methylliberine is characterized for use as a multi-analyte research tool in analytical and cell-based models examining redox modulation, cellular energy-related signaling, and neurochemical pathway mapping. In defined in-vitro environments, researchers employ the formulation to study electron-transfer dynamics, changes in cellular redox state, receptor- and transporter-level responses, second-messenger generation, and interaction networks between redox-active and neuroactive systems. Representative applications include assay development, comparative profiling of concentration-response relationships, time-course analyses, and mechanistic studies of mitochondrial and signaling-pathway behavior strictly within laboratory settings. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use
Dihexa (10mg) is a neuroactive peptide designed to enhance cognitive function by promoting the formation of new synaptic connections and supporting neuroplasticity in the brain. This compound has demonstrated the ability to improve memory, learning, and overall mental performance by mimicking brain-derived neurotrophic factor (BDNF) activity and activating key neural pathways. Dihexa supports long-term brain health by stimulating synaptogenesis and neuroregeneration, making it an ideal candidate for research in cognitive decline and age-related neurological conditions. In addition to its cognitive-enhancing effects, Dihexa has shown potential benefits for mood and focus, helping promote sharper mental clarity and emotional stability during high-demand cognitive tasks. Formulated for researchers exploring advanced nootropic agents, Dihexa (10mg) Tablets x30 provide a powerful tool for investigating cognitive repair and brain optimization applications.
• Composition and format Brain Blend - Dihexa (10 mg) / Tesofensine (250 mcg) / BPC-157 (125 mcg) x 60 Tablets is a fixed-combination research formulation supplied as solid-format tablets for controlled laboratory workflows. Each tablet contains 10 mg of Dihexa, 250 mcg of Tesofensine, and 125 mcg of BPC-157, with 60 tablets per container. The batch-specific Certificate of Analysis (COA) details compound identities, per-unit content, physical form, and relevant excipient information, supporting method-level reproducibility, mass-balance calculations, and documentation control in research settings. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use This Brain Blend is evaluated in controlled in-vitro systems investigating multi-target signaling, including neuroactive pathway models, energy-balance-related neurotransmitter systems, and peptide-mediated cell-communication networks, as well as pathway mapping in complex assay designs. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This combination of Dihexa, Tesofensine, and BPC-157 is characterized for use as a multi-analyte research reagent in analytical and cell-based models. Researchers employ the blend in defined in-vitro environments to examine concentration-response relationships, receptor and transporter engagement, downstream signaling cascades, and interaction networks among neuroactive and peptide pathways. Applications include comparative pathway profiling, assay development, and systems-level mapping of molecular feedback loops under controlled laboratory conditions only. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use
• Composition and format BPC-157 (500 mcg) is a synthetic pentadecapeptide supplied as 500 mcg per tablet, with 30 tablets per container for controlled laboratory workflows using solid-format test articles. The batch-specific Certificate of Analysis (COA) details peptide identity, peptide content per unit, physical form, and relevant excipient information, supporting method-level reproducibility, mass-balance calculations, and documentation control in research environments. • Analytical verification Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use. • Intended research use BPC-157 (500 mcg) is evaluated in controlled in-vitro systems investigating peptide-mediated signaling, including models focused on extracellular matrix regulation, cellular stress-response pathways, and related signal-transduction networks in defined assay platforms. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes in humans or animals. • Research characteristics and applications This synthetic peptide is characterized for use as a research reagent in analytical and cell-based models examining peptide-dependent modulation of signaling cascades, matrix-associated processes, and downstream molecular feedback loops. Researchers employ BPC-157 (500 mcg) in defined in-vitro environments to study concentration-response relationships, pathway activation profiles, and interaction networks at the cellular and molecular level, strictly within laboratory assay designs and not in any in-vivo context. • Manufacturing and documentation Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness. Research Use Only (RUO) Statement • For in-vitro research only • Not for human or animal consumption • Not for diagnostic or therapeutic use
5-Amino-1MQ (50mg) is a small-molecule NNMT inhibitor designed to increase NAD+ availability, enhance energy expenditure, and reduce fat cell size. This compound has been studied for its ability to improve metabolic function by shifting the body toward greater energy utilization and promoting fat oxidation. Research suggests 5-Amino-1MQ may support better insulin sensitivity and glucose regulation, making it relevant for metabolic and obesity-related studies. By modulating NAD+ pathways, 5-Amino-1MQ also supports mitochondrial performance, cellular energy, and longevity-related mechanisms. Formulated for researchers investigating fat loss, metabolic health, and cellular energy, 5-Amino-1MQ (50mg) Tablets x60 offer a unique pathway into advanced metabolic science.
5-Amino-1MQ is a small-molecule NNMT inhibitor designed to increase NAD+ availability, enhance energy expenditure, and reduce fat cell size. This compound has been studied for its ability to improve metabolic function by shifting the body toward greater energy utilization and promoting fat oxidation. Research suggests 5-Amino-1MQ may support better insulin sensitivity and glucose regulation, making it relevant for metabolic and obesity-related studies. By modulating NAD+ pathways, 5-Amino-1MQ also supports mitochondrial performance, cellular energy, and longevity-related mechanisms. Formulated for researchers investigating fat loss, metabolic health, and cellular energy, 5-Amino-1MQ Tablets x60 offer a unique pathway into advanced metabolic science.
